Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.

PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.

Studieoversikt

Detaljert beskrivelse

OBJECTIVES:

  • Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
  • Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
  • Determine the toxicity of pegylated interferon alfa in these patients.
  • Determine the compliance of these patients treated with pegylated interferon alfa.
  • Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
  • Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.

Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.

Patients are followed every 6 months for 5 years.

PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.

Studietype

Intervensjonell

Registrering (Faktiske)

1258

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Newcastle, Australia, NSW 2300
        • David Maddison Clincial Sciences
    • Victoria
      • East Melbourne, Victoria, Australia, 8006
        • Peter Maccallum Cancer Institute
      • Heidelberg West, Victoria, Australia, 3081
        • Austin and Repatriation Medical Centre
    • Western Australia
      • Perth, Western Australia, Australia, 6000
        • Royal Perth Hospital
      • Perth, Western Australia, Australia, 6009
        • Sir Charles Gairdner Hospital, Perth
      • Brussels, Belgia, 1200
        • Cliniques universitaires Saint-Luc
      • Brussels, Belgia, 1000
        • Institut Jules Bordet
      • Brussels, Belgia, 1070
        • Hopital Universitaire Erasme
      • Edegem, Belgia, B-2650
        • Universitair Ziekenhuis Antwerpen
      • Gosselies, Belgia, 6041
        • Clinique Notre Dame de Grâce
      • Leuven, Belgia, B-3000
        • U.Z. Gasthuisberg
      • Sofia, Bulgaria, 1756
        • National Centre of Oncology
      • Tallinn, Estland, 11619
        • North-Estonian Regional Hospital Cancer Centre
      • Amiens, Frankrike, 80054
        • Centre Hospitalier Universitare d'Amens
      • Besancon, Frankrike, 25030
        • CHR de Besancon - Hopital Saint-Jacques
      • Bordeaux, Frankrike, 33075
        • Hopital Saint André
      • Boulogne Billancourt, Frankrike, F-92104
        • CHU Ambroise Paré
      • Grenoble, Frankrike, 38043
        • Chr De Grenoble - La Tronche
      • Lille, Frankrike, 59037
        • Centre Hospitalier Regional et Universitaire de Lille
      • Limoges, Frankrike, 87042
        • Centre Hospital Regional Universitaire de Limoges
      • Lyon, Frankrike, 69373
        • Centre Léon Bérard
      • Montpellier, Frankrike, 34298
        • Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
      • Montpellier, Frankrike, 34295
        • Hopital St. Eloi
      • Nice, Frankrike, F-06202
        • Hopital L'Archet - 2
      • Paris, Frankrike, 75018
        • Hopital Bichat - Claude Bernard
      • Paris, Frankrike, 75475
        • Hôpital Saint-Louis
      • Pessac, Frankrike, 33604
        • Hopital Haut Lévêque
      • Reims, Frankrike, 51092
        • Centre Hospitalier Universitaire
      • Rennes, Frankrike, 35042
        • Centre Eugene Marquis
      • Saint Cloud, Frankrike, 92211
        • Centre René Huguenin
      • Saint Priest en Jarez, Frankrike, 42277
        • Centre Hospitalier Regional et Universitaire de Saint-Etienne
      • Strasbourg, Frankrike, 67091
        • Hopitaux Universitaire de Strasbourg
      • Thionville, Frankrike, 57126
        • Centre Hospitalier Régional Metz Thionville
      • Tours, Frankrike, 37044
        • Centre Hospitalier Universitaire Bretonneau de Tours
      • Vandoeuvre-les-Nancy, Frankrike, 54511
        • Centre Alexis Vautrin
      • Villejuif, Frankrike, F-94805
        • Institut Gustave Roussy
      • Haifa, Israel, 31096
        • Rambam Medical Center
      • Holon, Israel, 58100
        • Wolfson Medical Center
      • Tel-Aviv, Israel, 64239
        • Tel-Aviv Sourasky Medical Center
      • Aviano, Italia, 33081
        • Centro di Riferimento Oncologico - Aviano
      • Firenze, Italia, I-50011
        • Ospendale S.M. Annunziata-A.S.DI Firenze
      • Genoa (Genova), Italia, 16132
        • Istituto Nazionale per la Ricerca sul Cancro
      • Milano, Italia, 20141
        • European Institute of Oncology - Chemo Prevention
      • Milano (Milan), Italia, 20133
        • Istituto Nazionale per lo Studio e la Cura dei Tumori
      • Naples, Italia, 80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori
      • Rome, Italia, 00161
        • Istituto Regina Elena
      • Torino, Italia, 10126
        • Universita Degli Studi di Torino
      • Zagreb, Kroatia, 10000
        • University Hospital Sestre Milosrdnice
      • Amsterdam, Nederland, 1007 MB
        • Vrije Universiteit Medisch Centrum
      • Leiden, Nederland, 2300 CA
        • Leiden University Medical Center
      • Nijmegen, Nederland, NL-6500 HB
        • University Medical Center Nijmegen
      • Rotterdam, Nederland, 3075 EA
        • Erasmus University Medical Center
      • Utrecht, Nederland, 3584 CX
        • Academisch Ziekenhuis Utrecht
      • Poznan, Polen, 61 866
        • Great Poland Cancer Center
      • Warsaw, Polen, 02-781
        • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
      • Lisbon, Portugal, 1099-023 Codex
        • Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
      • Porto, Portugal, 4200
        • Instituto Portugues de Oncologia Centro do Porto, SA
      • Ljubljana, Slovenia, Sl-1000
        • Institute of Oncology, Ljubljana
      • Madrid, Spania, 28041
        • Hospital Universitario 12 de Octubre
      • Zaragoza, Spania, 50009
        • Hospital Clinico Universitario
      • Birmingham, Storbritannia, B29 6JD
        • Selly Oak Hospital at University Hospital NHS Trust
      • Oxford, Storbritannia, OX3 7LJ
        • Churchill Hospital
    • England
      • Bristol, England, Storbritannia, BS2 8ED
        • Bristol Haematology and Oncology Centre
      • Cambridge, England, Storbritannia, CB2 2QQ
        • Addenbrooke's NHS Trust
      • Cheltenham, England, Storbritannia, GL53 7AN
        • Cheltenham General Hospital
      • Exeter, England, Storbritannia, EX2 5DW
        • Royal Devon and Exeter Hospital
      • Guildford, England, Storbritannia, GU2 5XX
        • Royal Surrey County Hospital
      • Hull, England, Storbritannia, HU8 9HE
        • Princess Royal Hospital
      • Leeds, England, Storbritannia, LS9 7TF
        • St. James's Hospital
      • Leicester, England, Storbritannia, LE1 5WW
        • Leicester Royal Infirmary
      • London, England, Storbritannia, SW3 6JJ
        • Royal Marsden NHS Trust
      • London, England, Storbritannia, NW3 2QG
        • Royal Free Hospital
      • London, England, Storbritannia, SW17 0QT
        • St. George's Hospital
      • London, England, Storbritannia, EC1A 7BE
        • Saint Bartholomew's Hospital
      • London, England, Storbritannia, SE1 9RT
        • Guy's and St. Thomas' Hospitals NHS Trust
      • Merseyside, England, Storbritannia, CH63 4JY
        • Clatterbridge Centre for Oncology NHS Trust
      • Newcastle Upon Tyne, England, Storbritannia, NE4 6BE
        • Newcastle General Hospital
      • Salisbury, England, Storbritannia, SP2 8BJ
        • Salisbury District Hospital
      • Sheffield, England, Storbritannia, S1O 2SJ
        • Weston Park Hospital
      • Southampton, England, Storbritannia, SO16 6YD
        • Southampton General Hospital
      • Sutton, England, Storbritannia, SM2 5PT
        • Royal Marsden Hospital
      • Westcliff-On-Sea, England, Storbritannia, SS0 0RY
        • Southend NHS Trust Hospital
    • Northern Ireland
      • Belfast, Northern Ireland, Storbritannia, BT9 7AB
        • Belfast City Hospital Trust
    • Scotland
      • Dundee, Scotland, Storbritannia, DD1 9SY
        • Ninewells Hospital and Medical School
      • Glasgow, Scotland, Storbritannia, G11 6NT
        • Western Infirmary
    • Wales
      • Cardiff, Wales, Storbritannia, CF4 7XL
        • Velindre Cancer Center at Velinde Hospital
      • Aarau, Sveits, 5001
        • Kantonspital Aarau
      • Bern, Sveits, CH-3010
        • Inselspital, Bern
      • Chur, Sveits, CH-7000
        • Ratisches Kantons und Regionalspital
      • Zurich, Sveits, CH-8091
        • UniversitaetsSpital
      • Prague (Praha), Tsjekkisk Republikk, 128 08
        • Charles University Hospital
      • Istanbul, Tyrkia, 34296
        • Vakif Gureba Training Hospital
      • Izmir, Tyrkia, 35220
        • Ege University Medical School
      • Berlin, Tyskland, D-13122
        • Robert Roessle Klinik
      • Bochum 1, Tyskland, D-44791
        • Saint Josef Hospital
      • Dortmund, Tyskland, 44123
        • Stadt. Kliniken
      • Erlangen, Tyskland, D-91054
        • Universitaet Erlangen
      • Goettingen, Tyskland, D-37075
        • Georg August Universitaet
      • Hamburg, Tyskland, D-22765
        • Haematologisch-Onkologische Praxis Altona
      • Heidelberg, Tyskland, D-69115
        • Universitaets-Hautklinik Heidelberg
      • Leipzig, Tyskland, D-04103
        • Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
      • Magdeburg, Tyskland, D-39120
        • Otto - Von - Guericke - Universitaet Magdeburg
      • Mannheim, Tyskland, D-68135
        • Klinikum der Stadt Mannheim
      • Wuerzburg, Tyskland, D-97080
        • Universitaet Wuerzburg/Hautkrankheiten

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

DISEASE CHARACTERISTICS:

  • Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement

    • N1 disease

      • Microscopic, nonpalpable nodal involvement
      • Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
    • N2 disease

      • Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
    • Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
  • Complete resection of primary melanoma with adequate surgical margins
  • Full lymphadenectomy must be performed within 70 days of study
  • No mucous membrane melanoma or ocular melanoma
  • No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
  • No incompletely resected disease due to gross extracapsular extension

PATIENT CHARACTERISTICS:

Age:

  • 18 to 70

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC at least 3,000/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin at least 9 g/dL

Hepatic:

  • SGOT and SGPT less than 2 times upper limit of normal
  • No active hepatitis

Renal:

  • Creatinine less than 2.0 mg/dL

Cardiovascular:

  • No severe cardiovascular disease including the following:

    • Arrhythmias requiring chronic treatment
    • Congestive heart failure (New York Heart Association class III or IV)
    • Symptomatic ischemic heart disease

Other:

  • No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
  • No thyroid dysfunction unresponsive to therapy
  • No uncontrolled diabetes mellitus
  • No active autoimmune disease
  • No active and/or uncontrolled infection
  • No history of neuropsychiatric disorder requiring hospitalization
  • No known active alcohol or drug abuse
  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior interferon alfa
  • No prior immunotherapy for melanoma
  • No other concurrent immunologic or biologic therapy
  • No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)

Chemotherapy:

  • No prior chemotherapy for melanoma
  • No concurrent chemotherapy

Endocrine therapy:

  • No prior hormonal therapy for melanoma
  • No concurrent hormonal therapy
  • No concurrent chronic systemic corticosteroid therapy

Radiotherapy:

  • No prior radiotherapy for melanoma
  • No concurrent radiotherapy

Surgery:

  • See Disease Characteristics
  • Recovered from any prior recent surgery

Other:

  • At least 30 days since other prior experimental therapy
  • No other concurrent investigational drugs

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: observation
5 years observation + 5 years follow up
Eksperimentell: pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
distant-metastasis free-survival (DMFS)
Tidsramme: from randomization
distant-metastasis free-survival (DMFS) after randomization
from randomization

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
survival
Tidsramme: from randomization till death
duration of survival: time from randomization until death, whatever the cause
from randomization till death
toxicity
Tidsramme: from randomization
toxicity
from randomization

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
quality of life
Tidsramme: from randomization
Quality of life evaluation
from randomization

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Alexander M. M. Eggermont, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juni 2000

Primær fullføring (Faktiske)

1. august 2003

Datoer for studieregistrering

Først innsendt

11. september 2000

Først innsendt som oppfylte QC-kriteriene

26. januar 2003

Først lagt ut (Anslag)

27. januar 2003

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

10. februar 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. februar 2015

Sist bekreftet

1. februar 2015

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere